NCT04503772
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 4 or less distinct brain metastases & at least one metastasis with surgical indication; Patients must be affiliated with the French social security system
Exclusions: Patients with brain metastasis larger than 5 cm in diameter; Patients with leptomeningeal disease; Patients with a history of stereotactic radiosurgery (SRS) on the target metastasis for surgery
https://ClinicalTrials.gov/show/NCT04503772